NEW YORK, July 14, 2026, 15:10 (EDT)
AtaiBeckley Inc. NASDAQ:ATAI shares climbed 15.6% to about $5.75 in Tuesday afternoon trading as investors weighed final U.S. Food and Drug Administration guidance for psychedelic-drug trials. The document expects two monitors to remain with a patient throughout a treatment session, making BPL-003’s roughly two-hour clinic model more relevant to operating costs. Duration is now a cost variable.
The gain was much larger than those of the closest listed developers. Compass Pathways plc NASDAQ:CMPS rose 1.9%, Definium Therapeutics Inc. NASDAQ:DFTX added 5.2%, and the SPDR S&P Biotech ETF (NYSEARCA:XBI) was nearly flat. Jefferies Financial Group Inc. NYSE:JEF analysts wrote that “a friendlier regulatory environment should make psychedelics a more investable space.” The market reaction was not uniform. TipRanks
| Security | Last price | Intraday move |
|---|---|---|
| AtaiBeckley Inc. NASDAQ:ATAI | $5.75 | +15.6% |
| Compass Pathways plc NASDAQ:CMPS | $13.44 | +1.9% |
| Definium Therapeutics Inc. NASDAQ:DFTX | $45.94 | +5.2% |
| SPDR S&P Biotech ETF (NYSEARCA:XBI) | $155.48 | +0.1% |
Last available prices at 15:10 EDT; percentage moves calculated against prior closes.
The FDA expects the lead monitor to be an independently licensed healthcare provider with graduate-level professional training and psychotherapy experience. A second monitor should have a nursing or bachelor’s degree and at least one year of relevant clinical experience. When the lead is not a physician, a licensed doctor should be able to reach the site within 15 minutes. The guidance turns time into labor.
Atai said most participants in BPL-003’s Phase 2b trial met discharge criteria at the 90-minute assessment, with the average across study arms remaining within two hours. Compass says a COMP360 psilocybin experience typically lasts six to eight hours. Applying the FDA benchmark mechanically produces about four monitor-hours for BPL-003, versus 12 to 16 for COMP360—a monitor-hour means one staff member observing for one hour. That is 67% to 75% less direct observation time, though it is not a full treatment-cost estimate. The gap is large.
| Program | Published clinic or session window | Two-monitor observation load | Relative to BPL-003 |
|---|---|---|---|
| BPL-003 | About 2 hours | About 4 monitor-hours | Baseline |
| COMP360 | 6–8 hours | 12–16 monitor-hours | 3–4 times higher |
The calculation excludes preparation, follow-up, treatment-room costs and physician coverage.
Atai has also designed its commercial model around existing interventional-psychiatry workflows without requiring in-session psychotherapy. That may simplify one issue raised by the FDA, which wants sponsors to explain whether psychological support or psychotherapy contributes to the measured drug effect and how that model should be reflected in labeling. Chief Medical Officer Kevin Craig has said BPL-003 could offer “compelling practice economics.” That alignment matters. AtaiBeckley Inc.
The harder issue is functional unblinding—when patients or raters infer the treatment assignment from its noticeable effects. The FDA urged strong control groups, central blinded raters and double-blind data lasting at least 12 weeks for chronic illnesses. Atai’s two parallel Phase 3 studies use 12-week randomized, double-blind, placebo-controlled cores followed by 52-week open-label extensions; the company said FDA meeting minutes supported the proposed pivotal program. Approval to proceed is not proof of efficacy.
Execution now dominates the investment case. Atai said this month that BPL-003’s Phase 3 program had recently started, while VLS-01 Phase 2 results remain due in the fourth quarter. Cash, equivalents and short-term securities totaled $209.9 million at March 31, and management expects available funds to support operations into 2029 and through the anticipated BPL-003 Phase 3 readouts. The balance sheet buys time, not certainty.
About 9.35 million Atai shares had changed hands by mid-afternoon, roughly 25% above the stock’s 65-day average of 7.45 million before the closing bell. The shares were trading close to their session high of $5.77. The move had broad participation.
But the FDA guidance is nonbinding, and shorter sessions do not remove the burden of supplying two qualified monitors, rapid physician access and any driving studies or special post-approval safety controls regulators may seek. BPL-003 must still confirm efficacy, durability and safety in larger trials, while functional unblinding could make results harder to interpret. The market still wants proof.
Compass remains ahead in the regulatory race, with a rolling COMP360 application already under initial FDA review, final submission expected in the fourth quarter and a possible first-half 2027 launch subject to approval and federal rescheduling. Atai must now convert its shorter treatment window into clean Phase 3 data, while a September 14 FDA hearing on supervised and supportive psychedelic settings will offer another test of the emerging clinic model. Duration earned a premium today; data will decide whether it lasts.
